Seer develops the Proteograph suite of products—reagents, instruments, and software—that leverage proprietary engineered nanoparticles to enable unbiased, deep sampling of the proteome. The company says its technology can survey protein concentration ranges spanning many orders of magnitude and explore the >1 million protein variants postulated to exist across the human population. Seer positions its platform as a way to provide functional proteomic context to genomic datasets and to help identify precise biomarkers and novel therapeutic targets. It published results in Nature Communications demonstrating the nanoparticles’ ability to survey the proteome without bias. Seer plans a commercial launch of the Proteograph suite in 2021 and will use recent financing to expand research and development in advance of that launch. The company is led by CEO and founder Omid Farokhzad and is headquartered in Redwood City, Calif. Seer is a life sciences and health data company. The article reports the company announced a $17.5 million Series C. It also states that ex‑FDA chief Mark McClellan joined Seer's board. Hercules Capital made official the appointment of new CEO Scott Bluestein. The article does not disclose product details, operating metrics, or specific future plans.

Total raised

$73M

Funding rounds

2

Latest round

Series D

Latest activity

Dec 2019